Wockhardt has received approval for the transfer of business comprising 62 products and line extensions along with related business assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives; and manufacturing facility in Baddi, Himachal Pradesh, India, where some of the said pharmaceutical products which are being transferred are manufactured and together referred to as the Business Undertaking by way of a slump sale to Dr. Reddy's Laboratories for Rs 1,850 crore as per the terms and conditions specified in the Business Transfer Agreement (BTA).
The transaction is expected to be completed by May 12, 2020 (i.e. within 3 months from the date of execution of BTA). The Board of Directors of the company, at its meeting held on February 12, 2020 has considered and approved the same.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1882.20 |
Dr. Reddys Lab | 1377.55 |
Cipla | 1520.65 |
Lupin | 2309.65 |
Zydus Lifesciences | 957.80 |
View more.. |